中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.114 seconds)

    BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
    1.
    发明申请
    BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH 审中-公开
    用于治疗异常细胞生长的双相衍生物

    公开(公告)号：US20070072885A1

    公开(公告)日：2007-03-29

    申请号：US11422235

    申请日：2006-06-05

    Applicant: Samit Bhattacharya ,  Chandra Prakash

    Inventor： Samit Bhattacharya ,  Chandra Prakash

    IPC: A61K31/517 ,  C07D403/02

    CPC classification number: C07D239/94 ,  C07D401/12

    Abstract: The invention relates to substantially pure compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R2, R3, R5, and X are as defined herein, and wherein the compound of formula 1 optionally further comprises a hydroxy substituent, an O-glucuronic acid, or an N−>O (N-oxide) moiety. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders that contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

    Abstract translation: 本发明涉及基本上纯的式1化合物及其药学上可接受的盐，前药和溶剂化物，其中R 1，R 2，R 3， R 5，R 5如本文所定义，并且其中式1化合物任选地进一步包含羟基取代基，O-葡萄糖醛酸或N-（O-氧化物） ）部分。 本发明还涉及通过施用式1的化合物和用于治疗含有式1化合物的这种病症的药物组合物来治疗哺乳动物异常细胞生长的方法。本发明还涉及制备式1化合物的方法。

    S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
    3.
    发明申请
    S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders 审中-公开
    S-甲基 - 二氢 - 齐拉昔酮用于治疗精神病和眼部疾病

    公开(公告)号：US20060287336A1

    公开(公告)日：2006-12-21

    申请号：US09873973

    申请日：2001-06-04

    Applicant: Chandra Prakash ,  Terese Smolarek

    Inventor： Chandra Prakash ,  Terese Smolarek

    IPC: A61K31/496

    CPC classification number: A61K31/22 ,  A61K31/496

    Abstract: This invention relates to pharmaceutical compositions containing S-methyl-dihydro-ziprasidone and to the use of such compound and its pharmaceutically acceptable salts for the treatment of psychiatric and ocular disorders. More specifically, it relates to the use of such compound and its pharmaceutically acceptable salts for the treatment of a disorder or condition selected from: schizophrenia, anxiety disorders such as generalized anxiety disorder, panic disorder, posttraumatic stress disorder and phobias (e.g., social phobia, agoraphobia etc.); psychotic episodes of anxiety: anxiety, agitation, excessive aggression, tension, or social or emotional withdrawal associated with psychosis; psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder, and mood disorders associated with schizophrenia; behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder; dementias such as dementias associated with Alzheimer's disease; drug-induced and neurodegeneration based dyskinesias; obsessive compulsive disorder; Tourette's syndrome; glaucoma; and ischemic retinopathy.

    Abstract translation: 本发明涉及含有S-甲基 - 二氢 - 齐拉西酮的药物组合物以及这种化合物及其可药用盐在治疗精神病和眼部疾病中的用途。 更具体地说，它涉及这种化合物及其药学上可接受的盐在治疗选自以下的病症或病症中的用途：精神分裂症，焦虑症例如广泛性焦虑症，惊恐障碍，创伤后应激障碍和恐惧症（例如社交恐惧症 ，广场恐怖等）; 焦虑的精神病发作：与精神病有关的焦虑，激动，过度侵略，紧张或社会或情绪退缩; 精神病心理障碍如重度抑郁障碍; 与精神病性疾病相关的情绪障碍，例如与双相障碍相关的急性躁狂症和抑郁症，以及与精神分裂症相关的情绪障碍; 与精神发育迟滞，自闭症和行为障碍相关的行为障碍; 痴呆症如与阿尔茨海默病相关的痴呆; 药物诱导和神经退行性运动障碍; 强迫症 图雷特综合征 青光眼; 和缺血性视网膜病变。

Patent Agency Ranking